<p>N = 150 serial samples, belonging to 54 CML in follow-up* (*note that 1 CML patient with p230 transcripts was not included in this analysis).</p><p>Abbreviations: FCBA, Flow-cytometric Bead Assay, CHR = complete hematologic remission, CCyR = complete cytogenetic remission, MMR = major molecular response; (RQ-PCR) = quantitative real-time PCR; ELN = European Leukemia Net [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0130360#pone.0130360.ref008" target="_blank">8</a>]</p><p>Comparison of Flow-Cytometric Bead Assay (FCBA) vs. RQ-PCR for Detection of BCR-ABL1 Expression in CML Follow-Up.</p
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chroni...
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment ces...
Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson ...
<div><p>Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the ...
<p>* FCBA = Flow-cytometry Bead Assay; rMFI% range, 0.968–8.89; %BCR-ABL1<sup>IS</sup> range 0.313–1...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an important pract...
Background: Detection of BCR-ABL1 transcript level via real-time quantitative-polymerase-chain react...
We sought evidence of BCR/ABL transcripts in the peripheral blood of nine CML patients in complete c...
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::AB...
OBJECTIVES: Tyrosine kinase inhibitors (TKIs) have drastically changed the prospects for chronic mye...
Previous studies concerning BCR-ABL mRNA levels by quantitative real-time RT-PCR (Q-PCR) for chronic...
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chroni...
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment ces...
Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the Abelson ...
<div><p>Chronic Myeloid Leukemia (CML) is characterized by a balanced translocation juxtaposing the ...
<p>* FCBA = Flow-cytometry Bead Assay; rMFI% range, 0.968–8.89; %BCR-ABL1<sup>IS</sup> range 0.313–1...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-...
Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein, encoded by the Philadelphia...
Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an important pract...
Background: Detection of BCR-ABL1 transcript level via real-time quantitative-polymerase-chain react...
We sought evidence of BCR/ABL transcripts in the peripheral blood of nine CML patients in complete c...
Several studies have reported that chronic myeloid leukaemia (CML) patients expressing e14a2 BCR::AB...
OBJECTIVES: Tyrosine kinase inhibitors (TKIs) have drastically changed the prospects for chronic mye...
Previous studies concerning BCR-ABL mRNA levels by quantitative real-time RT-PCR (Q-PCR) for chronic...
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chroni...
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
In chronic myeloid leukemia (CML), the duration of deep molecular response (MR) before treatment ces...